세계의 유전체 편집/유전체 공학 시장

Global Genome Editing / Genome Engineering Market to Reach US$38.2 Billion by 2030

The global market for Genome Editing / Genome Engineering estimated at US$12.9 Billion in the year 2024, is expected to reach US$38.2 Billion by 2030, growing at a CAGR of 19.8% over the analysis period 2024-2030. CRISPR Technology, one of the segments analyzed in the report, is expected to record a 22.2% CAGR and reach US$18.7 Billion by the end of the analysis period. Growth in the ZFN Technology segment is estimated at 14.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.8 Billion While China is Forecast to Grow at 19.0% CAGR

The Genome Editing / Genome Engineering market in the U.S. is estimated at US$3.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.8 Billion by the year 2030 trailing a CAGR of 19.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.6% and 16.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.2% CAGR.

Global Genome Editing / Genome Engineering Market - Key Trends and Drivers Summarized

Why Is Genome Editing Revolutionizing Medicine, Agriculture, and Biotechnology?

Genome editing, also known as genome engineering, is at the forefront of scientific innovation, offering unprecedented possibilities in medicine, agriculture, and biotechnology. But why is genome editing so revolutionary in today's landscape? This technology allows scientists to make precise, targeted changes to an organism's DNA, enabling the correction of genetic defects, the enhancement of desirable traits, and the creation of new biological functions. Techniques like CRISPR-Cas9, TALENs, and zinc-finger nucleases have empowered researchers to modify specific genes with unmatched accuracy and efficiency, transforming the way we approach everything from treating genetic disorders to improving crop resilience.

In medicine, genome editing holds the promise of curing inherited diseases such as cystic fibrosis, sickle cell anemia, and muscular dystrophy by directly correcting the faulty genes responsible for these conditions. The technology is also being explored for cancer therapy, where it can be used to modify immune cells to target and destroy cancer cells more effectively. In agriculture, genome editing is helping develop crops that are more resistant to pests, diseases, and environmental stress, improving food security in the face of climate change. In biotechnology, this technology enables the creation of genetically modified organisms (GMOs) with novel traits, revolutionizing industries like pharmaceuticals, biofuels, and industrial enzymes. With its ability to fundamentally alter the genetic makeup of living organisms, genome editing is shaping the future of multiple sectors, making it one of the most impactful scientific advancements of our time.

How Are Technological Advancements Making Genome Editing More Precise and Accessible?

Technological advancements are significantly improving the precision, efficiency, and accessibility of genome editing, making it an even more powerful tool for research and clinical applications. One of the most groundbreaking innovations in this field is the development of CRISPR-Cas9, a gene-editing technology that has transformed the landscape of genome engineering. CRISPR-Cas9 allows for highly targeted DNA modifications by using a guide RNA to direct the Cas9 enzyme to a specific location in the genome, where it makes a precise cut. This system is not only faster and more efficient than previous genome editing methods, but it is also more flexible, allowing for a wide range of genetic modifications, from gene knockout to the insertion of new sequences.

Recent advancements in CRISPR technology have further enhanced its precision and versatility. For example, the development of base editing and prime editing techniques allows scientists to make single nucleotide changes or small edits to the genome without causing double-strand breaks, reducing the risk of unintended mutations or off-target effects. These advancements are particularly useful in therapeutic applications where precision is paramount. In addition, CRISPR's versatility has been expanded with the creation of "CRISPR libraries," which allow researchers to conduct large-scale genetic screens to identify genes involved in specific biological processes or diseases.

Another significant advancement is the increased accessibility of genome editing tools. CRISPR-Cas9 and related technologies have become widely available, with commercial kits and open-source platforms making genome editing more accessible to researchers worldwide. The simplicity and affordability of these tools have democratized genetic research, allowing smaller labs and institutions to engage in cutting-edge work that was once limited to well-funded laboratories. Additionally, advancements in delivery systems, such as viral vectors and nanoparticles, are improving the efficiency of delivering genome-editing components into target cells, making therapeutic applications more feasible.

Furthermore, the integration of artificial intelligence (AI) and machine learning in genome editing research is enhancing the ability to predict and minimize off-target effects. AI-driven algorithms can analyze vast amounts of genetic data to design more accurate guide RNAs, increasing the specificity of gene edits. This is particularly important for clinical applications, where minimizing unintended modifications is crucial for safety. These technological advancements are making genome editing more precise, scalable, and accessible, opening up new possibilities in medicine, agriculture, and biotechnology.

Why Is Genome Editing Essential for Advancing Medicine and Agriculture?

Genome editing is essential for advancing both medicine and agriculture because it enables targeted interventions that address critical challenges in human health and food security. In medicine, genome editing offers the potential to treat or even cure genetic diseases by directly correcting the underlying genetic mutations. Diseases like cystic fibrosis, Huntington's disease, and hemophilia, which are caused by single-gene mutations, are prime candidates for genome editing therapies. By using technologies like CRISPR-Cas9 to repair or replace defective genes, researchers are developing novel treatments that go beyond managing symptoms to address the root cause of the disease. For example, clinical trials using CRISPR-based therapies are already underway for blood disorders like sickle cell anemia and beta-thalassemia, showing promising results in correcting the genetic defects responsible for these conditions.

In addition to treating genetic disorders, genome editing is also being explored for cancer immunotherapy. Techniques like CAR-T cell therapy, which involves modifying a patient’s immune cells to better recognize and attack cancer cells, are being enhanced through genome editing to improve the specificity and effectiveness of these treatments. Moreover, genome editing has the potential to revolutionize regenerative medicine by enabling the modification of stem cells to generate tissues and organs for transplantation, offering new hope for patients with organ failure or severe injuries.

In agriculture, genome editing is playing a crucial role in enhancing crop resilience, yield, and nutritional value. With the global population expected to reach nearly 10 billion by 2050, food security is becoming an increasingly urgent issue. Genome editing allows scientists to develop crops that are resistant to pests, diseases, and environmental stressors such as drought and heat, helping to secure food supplies in the face of climate change. For example, CRISPR has been used to create disease-resistant wheat, drought-tolerant corn, and tomatoes with improved shelf life. These advancements not only help farmers reduce their reliance on chemical pesticides and fertilizers but also increase crop productivity, contributing to more sustainable agricultural practices.

In addition to improving resistance and yield, genome editing can enhance the nutritional value of crops. For example, rice has been genetically modified using CRISPR to increase its levels of beta-carotene, a precursor to vitamin A, addressing vitamin deficiencies in regions where rice is a staple food. Similarly, genome-edited crops with improved oil content, protein quality, or other nutritional enhancements have the potential to combat malnutrition and improve public health worldwide. By addressing some of the most pressing challenges in human health and agriculture, genome editing is positioned to have a transformative impact on both sectors.

What Factors Are Driving the Growth of the Genome Editing Market?

Several key factors are driving the rapid growth of the genome editing market, including increasing investment in biotechnology, the rising prevalence of genetic diseases, and advancements in genome editing technologies like CRISPR. First, the surge in investment from both the private and public sectors is significantly contributing to the growth of the genome editing market. Pharmaceutical companies, venture capital firms, and government agencies are pouring funds into genome editing research, recognizing its potential to revolutionize medicine, agriculture, and industry. This influx of capital is accelerating the development of genome-editing therapies and agricultural solutions, as well as driving innovations in related technologies like delivery systems and bioinformatics.

Second, the increasing prevalence of genetic diseases and cancer is creating a growing demand for advanced therapeutic solutions. As more genetic links to diseases are identified, there is a rising need for targeted treatments that can address these conditions at their genetic root. Genome editing offers a direct approach to correcting genetic mutations, making it an attractive option for treating a wide range of conditions, from inherited disorders to cancers and viral infections. The ability to potentially cure or significantly alter the course of these diseases is propelling the interest in genome-editing therapies, driving market growth.

Third, the rapid advancements in genome editing technologies, particularly the development of CRISPR-Cas9, are fueling the expansion of the market. CRISPR has revolutionized genome engineering by offering a more efficient, affordable, and versatile method for editing genes compared to earlier techniques like zinc-finger nucleases and TALENs. As CRISPR technology continues to improve, with the development of more precise editing tools like base editors and prime editors, the potential applications of genome editing are expanding, further driving the growth of the market. These advancements are making genome editing more accessible to a wider range of research institutions and industries, from pharmaceuticals to agriculture.

Additionally, the rise of personalized medicine is playing a major role in the growth of the genome editing market. As the medical field moves toward more tailored treatments based on a patient’s genetic makeup, genome editing is increasingly seen as a key tool in developing customized therapies. The ability to design treatments that target specific genetic mutations or pathways is enhancing the appeal of genome editing in clinical settings, particularly in cancer therapy and rare genetic disorders.

Regulatory support and increasing public awareness of the potential benefits of genome editing are also contributing to market expansion. Regulatory agencies like the FDA and EMA are beginning to approve genome editing-based therapies, signaling growing acceptance of these technologies in mainstream healthcare. Moreover, as public awareness of genome editing grows, driven by media coverage and scientific breakthroughs, there is increasing demand for therapies and innovations based on this technology.

In summary, the growth of the genome editing market is driven by significant investment in biotechnology, the rising prevalence of genetic diseases, advancements in genome editing technologies like CRISPR, the shift toward personalized medicine, and growing regulatory support. As genome editing continues to evolve, its applications in medicine, agriculture, and biotechnology will expand, shaping the future of healthcare, food production, and scientific research.

SCOPE OF STUDY:

The report analyzes the Genome Editing / Genome Engineering market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (CRISPR, ZFN, TALEN, Other Technologies); Delivery Method (Ex-Vivo, In-Vivo); Application (Genetic Engineering, Clinical Applications); End-Use (Pharma & Biotech Companies, Academic & Government Research Institutes, Contract Research Organizations)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 27 Featured) -

• CRISPR Therapeutics AG
• Editas Medicine, Inc.
• GenScript Biotech Corporation
• Horizon Discovery Group PLC
• Integrated DNA Technologies (IDT), Inc.
• Lonza Group AG
• Merck & Co., Inc.
• New England Biolabs, Inc.
• OriGene Technologies, Inc.
• Sangamo Therapeutics
• Thermo Fisher Scientific, Inc.
• Transposagen Biopharmaceuticals, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Genome Editing / Genome Engineering - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Advances in CRISPR Technology Revolutionize Genome Editing Applications
  • Expansion of Genome Editing Applications in Agriculture and Livestock
  • Role of Genome Editing in Personalized Medicine and Therapeutic Development
  • Growth of Therapeutic Applications Driving Market Opportunities
  • Implications of Germline and Somatic Cell Editing
  • Future Directions: Genome Editing in Neurodegenerative Diseases and Cancer
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Genetic Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 2: World 6-Year Perspective for Genetic Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 3: World Recent Past, Current & Future Analysis for Clinical Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 4: World 6-Year Perspective for Clinical Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for CRISPR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World 6-Year Perspective for CRISPR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for ZFN by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 8: World 6-Year Perspective for ZFN by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 9: World Recent Past, Current & Future Analysis for TALEN by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 10: World 6-Year Perspective for TALEN by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World 6-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Ex-Vivo by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 14: World 6-Year Perspective for Ex-Vivo by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 15: World Recent Past, Current & Future Analysis for In-Vivo by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 16: World 6-Year Perspective for In-Vivo by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World 6-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Academic & Government Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 20: World 6-Year Perspective for Academic & Government Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 21: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 22: World 6-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 23: World Genome Editing / Genome Engineering Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 24: World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 25: World 6-Year Perspective for Genome Editing / Genome Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA 6-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2025 & 2030
  • TABLE 28: USA Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 29: USA 6-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2025 & 2030
  • TABLE 30: USA Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 31: USA 6-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA 6-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2025 & 2030
• CANADA
  • TABLE 34: Canada Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 35: Canada 6-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2025 & 2030
  • TABLE 36: Canada Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 37: Canada 6-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2025 & 2030
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada 6-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2025 & 2030
  • TABLE 40: Canada Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 41: Canada 6-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2025 & 2030
• JAPAN
  • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 42: Japan Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 43: Japan 6-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2025 & 2030
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Japan 6-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2025 & 2030
  • TABLE 46: Japan Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 47: Japan 6-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2025 & 2030
  • TABLE 48: Japan Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 49: Japan 6-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2025 & 2030
• CHINA
  • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 50: China Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: China 6-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2025 & 2030
  • TABLE 52: China Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 53: China 6-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2025 & 2030
  • TABLE 54: China Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 55: China 6-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2025 & 2030
  • TABLE 56: China Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China 6-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2025 & 2030
• EUROPE
  • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 58: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 59: Europe 6-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2025 & 2030
  • TABLE 60: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 61: Europe 6-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2025 & 2030
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Europe 6-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2025 & 2030
  • TABLE 64: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 65: Europe 6-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2025 & 2030
  • TABLE 66: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 67: Europe 6-Year Perspective for Genome Editing / Genome Engineering by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
• FRANCE
  • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 68: France Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: France 6-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2025 & 2030
  • TABLE 70: France Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 71: France 6-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2025 & 2030
  • TABLE 72: France Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 73: France 6-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2025 & 2030
  • TABLE 74: France Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: France 6-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2025 & 2030
• GERMANY
  • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 76: Germany Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 77: Germany 6-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2025 & 2030
  • TABLE 78: Germany Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 79: Germany 6-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2025 & 2030
  • TABLE 80: Germany Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Germany 6-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2025 & 2030
  • TABLE 82: Germany Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 83: Germany 6-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2025 & 2030
• ITALY
  • TABLE 84: Italy Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 85: Italy 6-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2025 & 2030
  • TABLE 86: Italy Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Italy 6-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2025 & 2030
  • TABLE 88: Italy Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 89: Italy 6-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2025 & 2030
  • TABLE 90: Italy Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 91: Italy 6-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2025 & 2030
• UNITED KINGDOM
  • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 92: UK Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: UK 6-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2025 & 2030
  • TABLE 94: UK Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 95: UK 6-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2025 & 2030
  • TABLE 96: UK Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 97: UK 6-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2025 & 2030
  • TABLE 98: UK Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: UK 6-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 100: Rest of Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 101: Rest of Europe 6-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2025 & 2030
  • TABLE 102: Rest of Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 103: Rest of Europe 6-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2025 & 2030
  • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Rest of Europe 6-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2025 & 2030
  • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 107: Rest of Europe 6-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2025 & 2030
• ASIA-PACIFIC
  • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 108: Asia-Pacific Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 109: Asia-Pacific 6-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2025 & 2030
  • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Asia-Pacific 6-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2025 & 2030
  • TABLE 112: Asia-Pacific Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 113: Asia-Pacific 6-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2025 & 2030
  • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 115: Asia-Pacific 6-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 116: Rest of World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Rest of World 6-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2025 & 2030
  • TABLE 118: Rest of World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 119: Rest of World 6-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2025 & 2030
  • TABLE 120: Rest of World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 121: Rest of World 6-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2025 & 2030
  • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Rest of World 6-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2025 & 2030

IV. COMPETITION